{"name":"Insmed Incorporated","slug":"insmed-incorporated","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Tyvaso®","genericName":"Tyvaso®","slug":"tyvaso","indication":"Other","status":"marketed"},{"name":"[14C]-brensocatib","genericName":"[14C]-brensocatib","slug":"14c-brensocatib","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Tyvaso®","genericName":"Tyvaso®","slug":"tyvaso","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[14C]-brensocatib","genericName":"[14C]-brensocatib","slug":"14c-brensocatib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNU2NBenlMOVlYa0FYTWhDV3RVUk9qX1hQZ1p0NTVUTmdIV282UzRJYkRHcS1OV2NPNDRwR1B0NW1zdWlvWEZDVVJDYVhndnVvVFVLcm0xaHA0aWdDRmRSS1hvVXQxZ24zOWlpMk1qc0lnRmM3QWdiY2xCRGdBRVBtX0xUbmdOS0dCbWw4?oc=5","date":"2026-04-02","type":"pipeline","source":"BioSpace","summary":"The Top 12 Companies Hiring in Biopharma Now - BioSpace","headline":"The Top 12 Companies Hiring in Biopharma Now","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOcnZMWktFdlYtWTJjaFUwUUpqRExrZHY5d1RxYnNWTm1LVkJzNEd6bkNBRjZ2eDZkRnBRb2VsclF1RVEwVlU5bzFiSVFoX3FJZ21ZUjM3NmlMZW1nVzh6bWtFMEtVWGE3ZVc4MnpvbHB3TXlGV1hNT2NGQ1AySzFSaU5KdW0xYmRKTjB3?oc=5","date":"2026-04-01","type":"pipeline","source":"Finviz","summary":"Options Bulls Could Be Right About This Pharma Stock - Finviz","headline":"Options Bulls Could Be Right About This Pharma Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxPWG11YkM3NGdLeE15V21kSDdqV3pHeGRhWHA3UWIzZ25ReHlGY19MeWplODJxV1pLbHdSUF9JbFFxSGl4T2RBb2w0UUY1WkJ0emozRlNiZm1FOVZkYTExaDVDNW01NGh1WTAwTTdYaU5vRGRsNnRWeG1ucDBraThyYUgyUWVoakRJaVpaUjlvclpBUjlMcVVLcVYwd0owMWJkN3NPMWFOak1PcWkzdHhiVDhOQ00yU2doR21SWWlYTzNDUjh1dm5aampwZGRwdUdURVBjUU13V1J3V3NleDhVUnBGVnh3Ni1KZkRSNW1hNWEtSklYLTdKTnYtbk9jem9nWUh1VTlsVjM2WWIzT21ydA?oc=5","date":"2026-03-24","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Addus Homecare (ADUS) and Novo Nordisk (NVO) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Addus Homecare (ADUS) and Novo Nordisk (NVO)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNN1lCSXpfaU1hZjl2YkhMR3JqLUx3M2lKc0w5M0NGMXNuNmtUdVlVc2NlUlJkTkJ4MENKWTk5dHB1eW56VDVRRG00bEN4MmxTUlljVkZMSG5yZ3hkQ1RkdHFPaEJrYk9HWF9NM01FS2drdGhxVUFIb3pZMkpRM2l0RkhrWmxoMUZtN1ZaSENrUnhqcFdfRU00bDZBaHRqLTd2WmpmLXhCdW9qS1RSMWFPNlFzNmpvN3RYTFQzdlFuaU8?oc=5","date":"2026-02-16","type":"earnings","source":"TradingView","summary":"What to Expect From These Drug/Biotech Players This Earnings Season? - TradingView","headline":"What to Expect From These Drug/Biotech Players This Earnings Season?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOak5UeXhnaHNFYlhTTDFZSGdiYmRiN2prLVBYajhrS05qRW42M1RwX3RYYTdwUWJJQWFlVm1kTG9kbkFac3FTZzM4ZjkxUHhqN1pTS1ZqajV1T2ZTbXJrUHdyU0lYeDczeThCMWdkdGVmRUdKVHRDUVdPRXJ4YUlkRmhYYUpQM18waXZvaF82VnVXTHpMRFFicw?oc=5","date":"2025-12-18","type":"pipeline","source":"The Pharma Letter","summary":"Insmed adds to pipeline amid brensocatib failure - The Pharma Letter","headline":"Insmed adds to pipeline amid brensocatib failure","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOR0ZPdE5FSzNPSU9qUWNWWlB3bEtHbS1VNmxNV29lalZGNHpCSFZrY2pIbG5yZXk0YTFxbmR6Y0lLak0wT1d0dFdSd29MLUdPVDFLZ1A4aTMyNG9hTWJxZFJNd2lpMVFrOHREa0RaUk91dms4VXNnRGJIVlRLUGlSTUw3R25oa3RodlpsRUgtOW1PdGdFVUFOcEh5WGFmVlpreTh1c0hBenNmcnc?oc=5","date":"2025-11-19","type":"regulatory","source":"RTTNews","summary":"From Olema To Insmed: Are These High-Flying Biotechs Still Worth Buying? - RTTNews","headline":"From Olema To Insmed: Are These High-Flying Biotechs Still Worth Buying?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQYlNUR3g5RzJKZWFnaDhvdTBPWUNvOV96bF9NOXhsbXc3aHdaWDVLY19DY1drVHgwUHhWc0psVGVtc0o1Y3p2TGNFM1k2YjIzYUYxb2tLZ3FGNXd0ckNPdHotbUpOa2dKSUtuZEpOZlNXUjJsalMySlpXd256ZFJHbjNTNEZUZTc3WXIxemh6NmpVOGdOQUNkSmgwMDN6cTJxSGtJUw?oc=5","date":"2025-10-23","type":"pipeline","source":"Insmed Incorporated Investor Relations","summary":"Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List - Insmed Incorporated Investor Relations","headline":"Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNaDNQX0psSmpCUkoxNEcxaGUwQ2JOb1hDNzFMX3VUS0N6U0FYbFotNWVRWFhEbWpUWERmSU1UaXc0aFg1Qi1tZ2RWSW9SYS11TnpmRTVaY2RLUW9TcVNSNVlvSF9IYlVBaEl4WGRYaE5pWVpfR3drUTZMYVRNanlpZDEydk5ZLUIzRFNSTUFDUFBoYl9kWXFvMnRELUxfS2hiZWo1dWNZTDFia0haVFpzdkZxZll2U2lxd3c?oc=5","date":"2025-09-30","type":"pipeline","source":"Seeking Alpha","summary":"Insmed: De-Risked Respiratory Growth, Premium Multiple, And Real M&A Optionality - Seeking Alpha","headline":"Insmed: De-Risked Respiratory Growth, Premium Multiple, And Real M&A Optionality","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxOQnhiSmRlZE1aTU9fQ2E5YzgyYlNzWEhDYjl5dnZaZ1Z4azl5U3BuT1RTd0xJRERib3VPczVfMFdCaGlYZzc1VFI0UlVBb1c1TnB6a1MwcEw4R0Rudnc3aVFmMFJFREd1d0VTeFlNUVpqMG9zUEdPbkRLRUZHY3dfVlB3OHpOYXg0YUFyQ184Z1dkNmt4R2w2aXNzWm1rUGc5MWU1OFcyNkh1WFRYekJ5SkZSVjJFWjkzVjFGQ3RBYlBvQmhNOGxGU1FQQ1FDb0VyajRj?oc=5","date":"2025-08-13","type":"regulatory","source":"Reuters","summary":"US FDA approves Insmed's drug as first treatment for a chronic lung disease - Reuters","headline":"US FDA approves Insmed's drug as first treatment for a chronic lung disease","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxOck8wUDRYNDRpVWtkVTItZ3N6QTgxODRCMW1QazZNQ3poUzNZc05pUFBJbGR2UUJVckFNQWc1ZnQ5bll2ZV9yY0JaZjdmZHlBVlM4bnZhcGFnZzFFRkFtazF3dURfUTZ3N0RfZExYTHpPa3N1WlVTRU80RUdEeGcweTRwczFnWTFOY09jMjI4V19LV3VoZXlLeVk4M3F3RXA0NXE0VklydWpGYzR6Nk5PV0ZhWE1MNktTYXpic0JCVTBlSDJPZ3ZvOWxiQjN5djJLbWpMcTdfNA?oc=5","date":"2025-08-13","type":"regulatory","source":"Central New Jersey News","summary":"Bridgewater firm's stock jumps after FDA approves its new lung disease drug - Central New Jersey News","headline":"Bridgewater firm's stock jumps after FDA approves its new lung disease drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPLWpzdHV0SGFGbm03Mm1kSXhxbDVuTmNLYU84MjRPUzRaV3l4ZEp5eVdKbS1FRkpGZzVuRVh5dlMtNWZiaXdoQl9zVHlHQmhXeUVZYXhqaGw4QWZrQ2duWmFzQlNqNXVSNnFmRE1mbzBDdVlCYmxWQWI4QlJDdWd4WGp0b0c1LTFqTFhKUllsR19TQnFNcHk1QlN4QjhLLUNhSFdVbWdwajl1dTBIdHdENlFISU9FSHJBR2RmQ0VZVXc?oc=5","date":"2025-08-12","type":"regulatory","source":"Fierce Pharma","summary":"Insmed’s Brinsupri scores landmark FDA nod in bronchiectasis, marking first approval of a DPP1 inhibitor - Fierce Pharma","headline":"Insmed’s Brinsupri scores landmark FDA nod in bronchiectasis, marking first approval of a DPP1 inhibitor","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE05c2s2LXQ0aE44QXFBQzJnM21XaDRTRmFoM0RxWXVxYll4eXpaVGRqRUxGSjlDYmd3MklTVEEwTFlfU19DR3BzTFJYNGl6UFRQZ1lFWFlxdHNLdFVIb21kcDl3OU55MFJYNDlXZjBiMVhCQjBXaVFFWG5RVS13dw?oc=5","date":"2025-06-10","type":"trial","source":"Barron's","summary":"Insmed Stock Jumps 28% on Experimental Hypertension Drug Trial Results - Barron's","headline":"Insmed Stock Jumps 28% on Experimental Hypertension Drug Trial Results - Barron's","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_1":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}